Oneness Biotech Future Growth

Oneness Biotech is forecast to grow earnings and revenue by 20.6% and 86.9% per annum respectively while EPS is expected to grow by 20.7% per annum.

20.6%

Earnings growth rate

20.7%

EPS growth rate

Pharmaceuticals earnings growth	0%
Revenue growth rate	86.9%
Future return on equity	n/a
Analyst coverage	Low
Last updated	04 Oct 2024

No updates

Earnings and Revenue Growth Forecasts

BDL:ONES - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	332	-696	-493	-25,983	2
12/31/2024	122	-718	-856	8,668	2
6/30/2024	102	-979	-421	-343	N/A
3/31/2024	90	-1,141	-402	-307	N/A
12/31/2023	87	-1,313	-513	-422	N/A
9/30/2023	76	-1,469	-880	-772	N/A
6/30/2023	71	-967	-909	-823	N/A
3/31/2023	1,068	-293	-1,028	-944	N/A
12/31/2022	1,066	360	-970	-881	N/A
9/30/2022	1,069	1,131	-724	-648	N/A
6/30/2022	1,079	679	-706	-605	N/A
3/31/2022	75	-132	-700	-580	N/A
12/31/2021	66	-403	-389	-289	N/A
9/30/2021	52	-1,099	-287	-146	N/A
6/30/2021	30	-901	-217	-83	N/A
3/31/2021	49	64	160	314	N/A
12/31/2020	42	-242	5	158	N/A
9/30/2020	39	156	-46	52	N/A
6/30/2020	42	75	-12	72	N/A
3/31/2020	13	-481	-229	-186	N/A
12/31/2019	13	-322	-261	-213	N/A
9/30/2019	16	-202	-88	-10	N/A
6/30/2019	15	-255	-94	-2	N/A
3/31/2019	16	-209	-114	10	N/A
12/31/2018	19	-235	-172	-5	N/A
9/30/2018	15	-230	-338	-135	N/A
6/30/2018	12	-151	-382	-140	N/A
3/31/2018	10	-171	N/A	-157	N/A
12/31/2017	3	-155	N/A	-165	N/A
9/30/2017	3	-149	N/A	-176	N/A
6/30/2017	4	-34	N/A	-148	N/A
3/31/2017	5	-21	N/A	-128	N/A
12/31/2016	6	-14	N/A	-109	N/A
9/30/2016	6	-5	N/A	-96	N/A
6/30/2016	5	-106	N/A	-110	N/A
3/31/2016	9	-103	N/A	-139	N/A
12/31/2015	8	-93	N/A	-142	N/A
9/30/2015	7	-27	N/A	-120	N/A
6/30/2015	8	172	N/A	-145	N/A
3/31/2015	5	195	N/A	-157	N/A
12/31/2014	5	200	N/A	-151	N/A
9/30/2014	5	118	N/A	-167	N/A
6/30/2014	4	116	N/A	-130	N/A
3/31/2014	4	236	N/A	-93	N/A
12/31/2013	5	276	N/A	-89	N/A

Earnings vs Savings Rate: ONES is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ONES is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ONES is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ONES's revenue (86.9% per year) is forecast to grow faster than the Luxembourg market (4.9% per year).

High Growth Revenue: ONES's revenue (86.9% per year) is forecast to grow faster than 20% per year.

Future ROE: Insufficient data to determine if ONES's Return on Equity is forecast to be high in 3 years time